Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Citius Pharmaceuticals, Inc. on August 17, 2026. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Capital Market under the symbol "CTXR". The report addresses a specific regulatory matter regarding the Company's continued listing status.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on listing compliance and does not contain financial performance data.
Material Changes
On August 17, 2026, the Company received formal notice from Nasdaq granting an extension through February 8, 2027, to regain compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). The Company's stock continues to trade on the Nasdaq Capital Market during this extension period.
Outlook, Risks, and Management Commentary
- Compliance Requirement: To maintain listing, the bid price of the common stock must close at $1.00 per share or more for a minimum of ten consecutive business days before February 8, 2027.
- Delisting Risk: If the Company fails to regain compliance by the February 8, 2027 deadline, Nasdaq will issue a notice of delisting. The Company retains the right to appeal such a determination to a Nasdaq hearings panel.
- Management Action: The Company is currently evaluating options to regain compliance. Management explicitly states there can be no assurance that compliance will be achieved.
Key Facts for Investor Verification
- Verify the current trading price of CTXR to assess the feasibility of meeting the $1.00 bid price threshold.
- Monitor the stock's closing prices daily to track progress toward the ten consecutive business days requirement.
- Confirm the final deadline for compliance is February 8, 2027.
- Watch for future filings regarding potential appeals or alternative compliance strategies if the deadline is not met.